Tuesday, October 27, 2020
Machine learning and artificial intelligence have emerged as innovative ways to maximize the data that can be generated by liver biopsy samples. The goal of this session was to review the state of the field, and dive into the logistical, technical, and regulatory hurdles that must be addressed for these technologies to go from being used in exploratory fashion to being accepted for use in clinical trials.
Materials
Presentations
Innovative Tools for Quantitative Analysis of NAFLD Histology
Samer Gawrieh, Indiana University
HistoIndex
Dean Tai, HistoIndex
PathAI
Andrew Beck, PathAI
Pharmanest
Mathieu Petitjean, Pharmanest
Moderator:
Veronica Miller, Forum for Collaborative Research
Panelists:
Manal Abdelmalek, Duke University
Andrew Beck, PathAI
Pierre Bedossa, Institute of Translational Research, Newcastle University
Weijie Chen, U.S. Food and Drug Administration, CDRH
Samer Gawrieh, Indiana University
Prakash Jha, U.S. Food and Drug Administration, CDRH
David Kleiner, NIH National Cancer Institute
Mathieu Petitjean, Pharmanest
Vlad Ratziu, Hôpital Pitié Salpêtrière
Massimo Siciliano, Università Cattolica del Sacro Cuore / external AIFA / EMA consultant
Dean Tai, HistoIndex
